Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus
Sodium-glucose cotransporter 2 inhibitor tofogliflozin is a new type of antidiabetic drug for individuals with type 2 diabetes mellitus (T2DM). The aim of this study was to examine in which type of individuals and/or under which conditions tofogliflozin could exert more beneficial effects on body co...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2018/6470137 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849693974483173376 |
|---|---|
| author | Shinji Kamei Masahiro Iwamoto Miyuki Kameyama Masashi Shimoda Tomoe Kinoshita Atsushi Obata Tomohiko Kimura Hidenori Hirukawa Fuminori Tatsumi Kenji Kohara Shuhei Nakanishi Tomoatsu Mune Kohei Kaku Hideaki Kaneto |
| author_facet | Shinji Kamei Masahiro Iwamoto Miyuki Kameyama Masashi Shimoda Tomoe Kinoshita Atsushi Obata Tomohiko Kimura Hidenori Hirukawa Fuminori Tatsumi Kenji Kohara Shuhei Nakanishi Tomoatsu Mune Kohei Kaku Hideaki Kaneto |
| author_sort | Shinji Kamei |
| collection | DOAJ |
| description | Sodium-glucose cotransporter 2 inhibitor tofogliflozin is a new type of antidiabetic drug for individuals with type 2 diabetes mellitus (T2DM). The aim of this study was to examine in which type of individuals and/or under which conditions tofogliflozin could exert more beneficial effects on body composition and/or glycemic control in Japanese individuals with T2DM. We retrospectively evaluated the effects of tofogliflozin on body composition and/or glycemic control in individuals with T2DM who newly started taking tofogliflozin. After tofogliflozin treatment, body weight was significantly reduced and HbA1c levels were significantly decreased. Body fat mass, skeletal muscle mass, and skeletal muscle index, a marker for sarcopenia, were also reduced after the treatment. In univariate analyses, there was a statistically significant association between the decrease of HbA1c level after tofogliflozin treatment (Δ HbA1c) and the following parameters such as HbA1c levels at baseline, visceral fat area (VFA) at baseline, and reduction of VFA after the treatment (Δ VFA). Furthermore, in multivariate analyses, HbA1c levels at baseline and duration of diabetes were independently associated with Δ HbA1c. These results suggest that tofogliflozin would be more suitable for relatively obese individuals whose duration of diabetes is relatively short. |
| format | Article |
| id | doaj-art-4b824446fa7342d8955a5bc5384c7041 |
| institution | DOAJ |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-4b824446fa7342d8955a5bc5384c70412025-08-20T03:20:14ZengWileyJournal of Diabetes Research2314-67452314-67532018-01-01201810.1155/2018/64701376470137Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes MellitusShinji Kamei0Masahiro Iwamoto1Miyuki Kameyama2Masashi Shimoda3Tomoe Kinoshita4Atsushi Obata5Tomohiko Kimura6Hidenori Hirukawa7Fuminori Tatsumi8Kenji Kohara9Shuhei Nakanishi10Tomoatsu Mune11Kohei Kaku12Hideaki Kaneto13Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, JapanIwamoto Internal Medicine Clinic, Kagawa, JapanIwamoto Internal Medicine Clinic, Kagawa, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, JapanSodium-glucose cotransporter 2 inhibitor tofogliflozin is a new type of antidiabetic drug for individuals with type 2 diabetes mellitus (T2DM). The aim of this study was to examine in which type of individuals and/or under which conditions tofogliflozin could exert more beneficial effects on body composition and/or glycemic control in Japanese individuals with T2DM. We retrospectively evaluated the effects of tofogliflozin on body composition and/or glycemic control in individuals with T2DM who newly started taking tofogliflozin. After tofogliflozin treatment, body weight was significantly reduced and HbA1c levels were significantly decreased. Body fat mass, skeletal muscle mass, and skeletal muscle index, a marker for sarcopenia, were also reduced after the treatment. In univariate analyses, there was a statistically significant association between the decrease of HbA1c level after tofogliflozin treatment (Δ HbA1c) and the following parameters such as HbA1c levels at baseline, visceral fat area (VFA) at baseline, and reduction of VFA after the treatment (Δ VFA). Furthermore, in multivariate analyses, HbA1c levels at baseline and duration of diabetes were independently associated with Δ HbA1c. These results suggest that tofogliflozin would be more suitable for relatively obese individuals whose duration of diabetes is relatively short.http://dx.doi.org/10.1155/2018/6470137 |
| spellingShingle | Shinji Kamei Masahiro Iwamoto Miyuki Kameyama Masashi Shimoda Tomoe Kinoshita Atsushi Obata Tomohiko Kimura Hidenori Hirukawa Fuminori Tatsumi Kenji Kohara Shuhei Nakanishi Tomoatsu Mune Kohei Kaku Hideaki Kaneto Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus Journal of Diabetes Research |
| title | Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus |
| title_full | Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus |
| title_fullStr | Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus |
| title_full_unstemmed | Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus |
| title_short | Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus |
| title_sort | effect of tofogliflozin on body composition and glycemic control in japanese subjects with type 2 diabetes mellitus |
| url | http://dx.doi.org/10.1155/2018/6470137 |
| work_keys_str_mv | AT shinjikamei effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus AT masahiroiwamoto effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus AT miyukikameyama effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus AT masashishimoda effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus AT tomoekinoshita effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus AT atsushiobata effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus AT tomohikokimura effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus AT hidenorihirukawa effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus AT fuminoritatsumi effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus AT kenjikohara effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus AT shuheinakanishi effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus AT tomoatsumune effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus AT koheikaku effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus AT hideakikaneto effectoftofogliflozinonbodycompositionandglycemiccontrolinjapanesesubjectswithtype2diabetesmellitus |